DNMT3A and therapy-related myeloid neoplasm: TP53 gene mutation was significantly associated with development of treatment related myeloid neoplasm (tMN, odds ratio [OR] 1.69 [CI 1.18 – 1.97], logistic regression, Figure 3B) while DNMT3A mutations were protective (OR 0.688, [CI 0.506 – 0.933], logistic regression, Figure 3B).